Plus Therapeutics, Inc. (NASDAQ:PSTV) Expected to Announce Earnings of -$0.17 Per Share

Analysts expect Plus Therapeutics, Inc. (NASDAQ:PSTVGet Rating) to report ($0.17) earnings per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Plus Therapeutics’ earnings. Plus Therapeutics reported earnings per share of ($0.33) in the same quarter last year, which suggests a positive year over year growth rate of 48.5%. The business is scheduled to issue its next quarterly earnings report after the market closes on Monday, January 1st.

On average, analysts expect that Plus Therapeutics will report full year earnings of ($0.71) per share for the current financial year. For the next financial year, analysts forecast that the company will report earnings of ($0.59) per share. Zacks’ EPS calculations are an average based on a survey of research firms that follow Plus Therapeutics.

PSTV has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Plus Therapeutics in a research note on Friday, February 25th. Zacks Investment Research upgraded shares of Plus Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a research report on Thursday, March 24th.

A number of large investors have recently added to or reduced their stakes in PSTV. Geode Capital Management LLC lifted its position in shares of Plus Therapeutics by 97.6% in the third quarter. Geode Capital Management LLC now owns 258,437 shares of the company’s stock worth $493,000 after purchasing an additional 127,644 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in Plus Therapeutics in the 4th quarter worth approximately $217,000. Citadel Advisors LLC acquired a new stake in shares of Plus Therapeutics during the 2nd quarter valued at $111,000. Finally, Susquehanna International Group LLP purchased a new position in shares of Plus Therapeutics during the 4th quarter valued at $35,000. 8.46% of the stock is currently owned by institutional investors.

Shares of PSTV opened at $0.91 on Friday. The business has a 50-day moving average of $1.00. The stock has a market cap of $13.96 million, a PE ratio of -0.80 and a beta of 0.24. Plus Therapeutics has a 1-year low of $0.81 and a 1-year high of $3.54. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.36 and a quick ratio of 3.36.

Plus Therapeutics Company Profile (Get Rating)

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.

Recommended Stories

Get a free copy of the Zacks research report on Plus Therapeutics (PSTV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with's FREE daily email newsletter.